（编辑 王雪儿） 证券日报网讯 会通股份11月20日在互动平台回答投资者提问时表示，公司阻燃材料应用领域广泛，公 司围绕目前常见的通用塑料以及工程塑料均有对应的不同等级的阻燃方案，在家电、汽车、消费电子、 光伏等众多行业中均有应用。其中，围绕着家电领域的涉电部件如电控盒等应用场景推出完善的阻燃材 料解决方案；在汽车电子电器系统中，针对新能源车辆线束、连接系统、"三电"系统及充电相关部件， 公司推出低析出、低模垢阻燃尼龙材料、防火高CTI尼龙材料等材料解决方案，聚焦电器安全与可靠性 提升；在连接器领域，公司研发出了耐寒红磷阻燃增强尼龙材料，成功应用于光伏连接器，新能源连接 器等关键部件。 ...

Core Insights - Technological innovation is deemed essential for the vitality of enterprises, particularly in the materials sector, where stagnation leads to regression [1][2] - The company, Guangdong Jushi Chemical Co., Ltd., focuses on flame retardant and polymer materials, with plans to expand into new materials required for emerging sectors such as renewable energy, low-altitude economy, photovoltaics, and robotics [1][2] Company Development - Jushi Chemical has evolved into a publicly listed company on the Sci-Tech Innovation Board, with a core focus on flame retardant materials [2] - The company has significantly increased its R&D investment, with R&D expenses reaching 128 million yuan in 2023, accounting for 3.5% of revenue, and projected to rise to 139 million yuan in 2024 [2] Innovation and Patents - The company has achieved substantial breakthroughs in core technologies, filling domestic gaps, including the successful application of high-performance fireproof coatings in oil drilling platforms, disrupting the long-standing international monopoly [2] - As of June this year, the company has obtained a total of 425 authorized patents, including 234 invention and overseas patents [2] Future Directions - The company aims to maintain its focus on flame retardant and polymer materials while exploring biodegradable, low-carbon, and circular economy directions [2] - Plans include enhancing market competitiveness and expanding both domestic and international market presence, promoting "Chinese flame retardant technology" globally [2]

Group 1: Japanese Chemical Industry Investment in China - Japanese chemical companies have significantly increased their investments in China's chemical industry, with over 8 investments totaling more than 30 billion RMB in the past year [4][5] - Factors contributing to this investment surge include the structural adjustments of both countries' industries, long-term development benefits of the Chinese market, and strategic considerations of Japanese companies [4][5] - The rapid development of China's chemical industry, particularly in green technology and new materials, aligns with Japan's strengths, creating complementary opportunities [5] Group 2: Challenges and Strategic Shifts - A survey by the Japan Policy Investment Bank revealed that 42.6% of large Japanese manufacturing firms plan to reduce their operations in China, the highest level recorded [6] - The U.S.-China trade dispute is a primary driver for this strategic shift, with over 40% of firms citing "diversifying supply chain risks" as a key reason for scaling back [6] - Despite these challenges, many Japanese companies remain deeply embedded in China's local supply chains, making withdrawal impractical [6] Group 3: Toyota's Third-Country Supply Chain Strategy - Toyota has adopted a "third-country supply chain" model to mitigate geopolitical risks, exemplified by its partnership with Thailand's Summit Group to produce low-cost auto parts for electric vehicles [7] - This strategy aims to reduce electric vehicle production costs by 30% while leveraging the cost advantages of Southeast Asia and the quality of Chinese components [7] Group 4: Panasonic's Home Technology Business - Panasonic has established its first independent residential equipment company in China, despite the ongoing downturn in the real estate market [8] - The company is poised to capitalize on structural opportunities, as many older homes are undergoing renovations, driven by consumers seeking high-quality living environments [8] - Panasonic's home business is expected to reach a revenue scale of 10 billion RMB, with projections indicating a threefold increase by 2025 [9]

Financial Data and Key Metrics Changes - The company reported second quarter organic sales growth of 0.6% and adjusted EPS growth of 5% to $0.80, slightly ahead of guidance [6][11] - Adjusted EBITDA margin expanded by 30 basis points to 17.2%, driven by favorable mix and productivity initiatives [6][11] - For the first half of the year, organic sales grew about 1%, with expectations for a similar demand environment in the second half [7][11] Business Line Data and Key Metrics Changes - The Color Additives and Inks segment saw adjusted EBITDA grow 4% despite a 2% decline in organic sales, with weaker demand in consumer and transportation markets [16][17] - Specialty Engineered Materials segment grew organic sales by 6%, driven by strong growth in defense and healthcare, with healthcare growing double digits [18][19] - Packaging Materials segment's sales were muted, but EBITDA margins expanded by 100 basis points through cost improvement initiatives [16][17] Market Data and Key Metrics Changes - In the U.S. and Canada, sales increased by 1% year over year, led by healthcare and defense, offsetting weaker demand in other sectors [20] - EMEA sales were slightly down, with robust healthcare and defense sales but muted packaging sales [21] - Latin America grew 6%, marking its sixth consecutive quarter of growth, while Asia delivered 3% organic growth [21] Company Strategy and Development Direction - The company aims to evolve from a specialty formulator to an innovator of material solutions, with a focus on strategic structural changes in R&D to enhance product differentiation [10][12] - The operational playbook is designed to navigate low demand and high uncertainty, targeting approximately $40 million in benefits for 2025 [8][12] - Continued investment in growth vectors and strategic initiatives is prioritized, with a focus on healthcare, defense, and telecommunications as key growth drivers [12][19] Management's Comments on Operating Environment and Future Outlook - Management noted that market trends are not improving, with customers remaining in a wait-and-see mode, particularly in consumer markets [6][7] - The company expects Q3 to mirror Q2, with continued strength in defense and healthcare offsetting consumer weakness [7][22] - There is cautious optimism regarding the second half of the year, with expectations for adjusted EPS of $0.70, representing 8% growth year over year [22][23] Other Important Information - The company has a strong cash position, having paid down $50 million of debt during the quarter, and is on track to reduce total debt by $100 million to $200 million by year-end [12][23] - Patent filings increased by 50% in 2024 compared to 2023, indicating a focus on innovation [13] - The company expects CapEx for the year to be approximately $110 million and free cash flow to range from $190 million to $210 million [23] Q&A Session Summary Question: Is there any pre-buying activity affecting sales? - Management indicated no significant pre-buying activity has been observed, as customers are managing inventory tightly in uncertain demand environments [26][28] Question: What is the outlook for raw material inflation? - The company expects raw material inflation to remain at 1% to 2%, with some fluctuations in specific materials [30][31] Question: What is the outlook for volume in the second half? - Management expects a continuation of trends from the first half, with healthcare, defense, and telecommunications driving growth, while consumer and packaging markets may see slight declines [35][36] Question: How has consumer weakness evolved? - Consumer sales were flat in Q1 but down 8% in Q2, with significant weakness noted in the U.S. and Canada [45][46] Question: What is the impact of planned maintenance on EBITDA? - The planned maintenance impacted EBITDA by approximately $3 million in Q2, but margins are expected to expand in the second half [47][48] Question: Are customers pressuring to absorb tariff costs? - Management acknowledged pressure from customers regarding pricing due to increased tariffs, but they are working to manage costs and maintain pricing [51][52] Question: Can you provide context on the healthcare growth? - Healthcare has shown strong growth, particularly in medical devices and drug delivery, with a long-term positive outlook [61][62] Question: What are the trends in key markets in China? - The color business in China is under pressure due to government policies, but growth is expected in high-performance computing [67][68]

Group 1: Yishitong - Yishitong has made progress in several new material projects, including solid oxide battery (SOC) systems, high-purity quartz sand, bismuth stone, thermally conductive spherical alumina, and flame-retardant materials [1] - The SOC system project is progressing as planned, with the single battery pilot line operating stably, and the stack pilot production line expected to be completed by 2025 [1] - High-purity quartz sand's technical indicators and performance optimization have been completed, with plans to test in a single crystal factory by 2025 and establish a thousand-ton pilot line [1] - Bismuth stone shipments are expected to increase in 2024, with a slight decrease in price, and significant shipment growth anticipated in Q1 2025 [1] - The sales revenue of ceramic flame-retardant materials is increasing, with plans to expand into more application scenarios [1] Group 2: Desay Battery - Desay Battery anticipates uncertainties in the macroeconomic environment but aims to explore new markets and businesses for performance growth [2] - In 2024, revenue from smartphone battery business is expected to decline by 10.39%, influenced by both volume and price [2] - In Q1 2025, revenue from smartphone batteries is projected to grow by 8.97%, while wearable device batteries are expected to increase by 15.79% [2] - Revenue from electric tools, smart home, and mobility businesses is expected to grow by 24.37%, while energy storage business revenue is projected to decline by 14.86% [2] - The company plans to continue expanding production capacity in Vietnam, with expected revenue growth in Vietnam to double compared to last year [2] Group 3: Yahui Pharmaceutical - Yahui Pharmaceutical has made progress in the approval and commercialization of APL-1702, with the listing application accepted and review underway [3] - APL-2501 has completed multiple experiments, with IND submission expected by mid-2026, showing strong clinical competitive potential [3] - The company is targeting patients with strong willingness to pay for the initial positioning of Haikewei, gradually promoting blue light cystoscopy technology as a standard solution [3] - APL-2302 shows good pharmacokinetic characteristics and significant anti-tumor effects, having entered clinical research [3] - The company expects rapid revenue growth in 2024 and plans to upgrade its commercialization system in 2025, including hiring a Chief Commercial Officer and optimizing the organizational structure [3]